Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VOYDEYA safely and effectively. See full prescribing information for VOYDEYA. VOYDEYA® (danicopan) tablets, for oral use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.
- generic_name
- danicopan
- product_names
- Danicopan
- ndc
- 25682-043, 25682-043-92, 25682-046, 25682-046-92, 25682-040, 25682-040-90, 25682-043-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en